SynthesisFrontiers in pharmacology2026
Preclinical efficacy and safety of drug-loaded porous silicon nanoparticles for cancer treatment: a systematic review of
Synthesis in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Porous silicon nanoparticles (pSiNPs) are promising carriers for anticancer therapy because of their high drug-loading capacity, modifiable surface properties, and potential for stimulus-responsive drug release. This systematic review assessed the efficacy and safety of drug-loaded pSiNPs in in vitro and Methods: Searches were conducted from database inception to 30 July 2026. Eligible studies were controlled original investigations evaluating pSiNPs loaded with at least one anticancer drug and reporting quantitative antitumor outcomes. Study selection followed PRISMA 2020 guidelines, and the protocol was registered in PROSPERO (CRD420251076592). Given the substantial methodological heterogeneity, findings were synthesized narratively. Results: The search strategy identified 974 records, of which 22 met the inclusion; eight included animal experiments. Targeting ligands, polymeric coatings, and pH-, redox-, magnetic-, or near-infrared-responsive systems generally improved cellular uptake, drug release, cytotoxicity, and antitumor activity relative to study-specific comparators. Most Conclusion: Drug-loaded pSiNPs show promising preclinical anticancer activity, but the evidence is dominated by Systematic Review Registration: https://www.crd.york.ac.uk/PROSPERO/view/CRD420251076592.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.